BD Biosciences and Dyax Corp. Announce Research Products and Proteomics Alliance
FRANKLIN LAKES, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 13, 2001--BD Biosciences (BDB), a division of BD (Becton, Dickinson and Company) (NYSE:BDX - news), and Dyax Corp. (Nasdaq: DYAX - news) today announced the establishment of a strategic relationship for the discovery of antibodies using Dyax's proprietary phage display technology. Under the terms of the collaboration, BDB has obtained rights to antibodies identified using Dyax's proprietary human antibody library and screening technology.
BDB will have the exclusive right to market the Dyax antibodies as research products to the life science market. Dyax has retained all rights to use these antibodies in the therapeutic field. Each company has the right to collaborate with others to develop proteomics products using these antibodies.
According to Deborah J. Neff, President, BD Biosciences, ``Our partnership with Dyax is a fundamental step to position BDB to be a leader in the rapidly emerging field of proteomics. BDB, through its Pharmingen, Transduction Laboratories and Immunocytometry Systems product groups, already is a world leader in providing antibodies against cellular and intracellular markers in human, mouse and other species. Dyax's phage display technology will accelerate the generation of thousands of new antibodies significantly enhancing BDB's position as the partner of choice in proteomics.''
``BDB is an ideal partner to drive the power of phage display technology in the research products and proteomics fields,'' said Henry Blair, Chairman and Chief Executive Officer of Dyax Corp. ``This is another case of Dyax collaborating with a world leader to exploit the power of phage display in their market, generating both short term revenue and royalties for Dyax. Our corporate partnering strategy provides resources and focus to support Dyax's principal objective, the development of human therapeutic products.''
BDB provides innovative tools, systems and solutions supporting the life sciences around the world, accelerating the pace of discovery and diagnosis. From genes to proteins to cells, BDB offers integrated, high-value applications in drug discovery and development, flow cytometry systems, immune function monitoring, and functional genomics. With fiscal year 2000 revenues of approximately $550 million, BD Biosciences is comprised of Clontech Laboratories, Discovery Labware, Immunocytometry Systems, Pharmingen and Transduction Laboratories, names that have been known and trusted in the life sciences for years... |
